← Patent-cliff monitor small molecule INGREZZA VALBENAZINE TOSYLATE
Loss of exclusivity August 2040 latest FDA-listed patent expiry
Drug detail Brand name INGREZZA Active ingredient VALBENAZINE TOSYLATE Strength EQ 40MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval April 2017 Marketing status RX
Listed patents Patent Expires Type 10940141 August 2040 use U-1995 11026931 August 2039 use U-1995 11654142 November 2038 use U-3055 11026939 September 2038 product 11311532 September 2038 product 11040029 October 2037 use U-1995 10874648 October 2037 use U-3055 10952997 October 2037 use U-1995 10857148 October 2037 use U-1995 10857137 October 2037 use U-1995 11439629 October 2037 use U-3055 10993941 October 2037 use U-1995 10912771 October 2037 use U-3076 10906903 December 2036 substance, product 10906902 December 2036 substance, product 10919892 December 2036 substance, product 10851104 October 2036 substance 10851103 October 2036 substance, product 10844058 October 2036 substance, product 10065952 October 2036 substance, product 8039627 April 2031 substance, product 8357697 November 2027 use U-1995
Regulatory exclusivity Code Expires ODE-440 August 2030 I-925 August 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.